What is Zacks Research's Forecast for Surmodics Q1 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Analysts at Zacks Research reduced their Q1 2027 EPS estimates for Surmodics in a research note issued to investors on Tuesday, July 1st. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' FY2027 earnings at $0.28 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative return on equity of 7.10% and a negative net margin of 16.34%.

A number of other analysts have also recently issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Friday, March 7th.

Surmodics Trading Down 1.0%

Shares of NASDAQ SRDX traded down $0.28 during midday trading on Wednesday, reaching $29.00. 64,032 shares of the stock were exchanged, compared to its average volume of 229,856. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The stock has a 50 day moving average price of $28.86 and a 200-day moving average price of $31.97. The company has a current ratio of 5.14, a quick ratio of 3.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $414.70 million, a P/E ratio of -20.86 and a beta of 1.31.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Gabelli Funds LLC boosted its position in shares of Surmodics by 16.3% in the 1st quarter. Gabelli Funds LLC now owns 395,509 shares of the company's stock valued at $12,075,000 after purchasing an additional 55,550 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Surmodics during the 4th quarter valued at about $11,880,000. Hsbc Holdings PLC increased its stake in shares of Surmodics by 4.8% during the 1st quarter. Hsbc Holdings PLC now owns 267,042 shares of the company's stock worth $8,252,000 after purchasing an additional 12,344 shares during the last quarter. Gardner Lewis Asset Management L P boosted its position in Surmodics by 23.5% during the fourth quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock worth $10,410,000 after purchasing an additional 49,944 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company's stock worth $6,304,000 after purchasing an additional 86,143 shares during the period. Institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).